What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Paul G. Richardson spends much of his time researching Multiple myeloma, Internal medicine, Bortezomib, Cancer research and Surgery.
His work carried out in the field of Multiple myeloma brings together such families of science as Pharmacology and Dexamethasone.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
The Bortezomib study which covers Proteasome inhibitor that intersects with Angiogenesis.
The study incorporates disciplines such as Cell culture, Apoptosis, Protein kinase B, Cell growth and Bone marrow in addition to Cancer research.
His studies in Surgery integrate themes in fields like Ixazomib and Hazard ratio.
His most cited work include:
- Initial sequencing and analysis of the human genome. (18816 citations)
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Multiple myeloma, Bortezomib, Oncology and Lenalidomide.
His Internal medicine research includes elements of Gastroenterology and Surgery.
His Multiple myeloma research incorporates themes from Cancer research and Dexamethasone.
His Bortezomib course of study focuses on Pharmacology and In vivo.
His Oncology research is multidisciplinary, incorporating elements of Relapsed refractory, Clinical trial, Refractory Multiple Myeloma and Daratumumab.
His Lenalidomide study combines topics in areas such as Regimen, Tolerability and Maintenance therapy.
He most often published in these fields:
- Internal medicine (49.35%)
- Multiple myeloma (47.24%)
- Bortezomib (31.29%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (49.35%)
- Multiple myeloma (47.24%)
- Oncology (23.65%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide.
His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Defibrotide.
His study focuses on the intersection of Multiple myeloma and fields such as Cancer research with connections in the field of Immune system.
His Dexamethasone research is multidisciplinary, incorporating perspectives in Clinical endpoint, Refractory and Subgroup analysis.
He has researched Lenalidomide in several fields, including Maintenance therapy, Progression-free survival, Neutropenia and Hazard ratio.
His biological study spans a wide range of topics, including Proteasome inhibitor, Proteasome and Phases of clinical research.
Between 2017 and 2021, his most popular works were:
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. (191 citations)
- Oral selinexor-dexamethasone for triple-class refractory multiple myeloma (149 citations)
- CD38 antibodies in multiple myeloma: back to the future. (147 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Paul G. Richardson mainly investigates Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide.
His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
As part of his studies on Multiple myeloma, Paul G. Richardson frequently links adjacent subjects like Progression-free survival.
His research integrates issues of Clinical trial, Refractory, Stem cell, Disease and Monoclonal antibody in his study of Oncology.
His Dexamethasone research includes themes of Relapsed refractory, Clinical endpoint and Cancer research.
His study looks at the relationship between Bortezomib and fields such as Proteasome inhibitor, as well as how they intersect with chemical problems.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
